首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
Chemotherapy drug 5-fluorouracil (5-FU) is the first-line treatment for colorectal cancer (CRC); however, 5-FU resistance decreases CRC therapeutic efficiency. A previous study revealed that microRNA (miR)-9-5p serves an antitumor effect in CRC. However, the effect of miR-9-5p in CRC chemoresistance remains unknown. In the present study, two CRC cell lines, including HT-29 and HCT-116 cells, were used to investigate the impact of miR-9-5p in overcoming 5-FU resistance. The results revealed that treatment with 5-FU decreased CRC cell viability and upregulated miR-9-5p expression in both CRC cells. Knockdown of miR-9-5p decreased HCT-116 cell sensitivity to 5-FU and inhibited apoptosis. By contrast, miR-9-5p overexpression enhanced the sensitivity of HT-29 cells to 5-FU and induced apoptosis. Additionally, it was confirmed that miR-9-5p directly targeted high mobility group A2 (HMGA2). HMGA2 overexpression reversed miR-9-5p-induced HT-29 apoptosis. The present study indicated that miR-9-5p enhanced the sensitivity of CRC cells to 5-FU via downregulating HMGA2 expression.  相似文献   

5.
Osteosarcoma is a malignant bone tumor that commonly occurs in young individuals. It accounts for 10% of solid tumors in those who are 15–19 years old. MicroRNA (miRNA/miR) dysregulation serves a crucial role in the molecular mechanism of osteosarcoma. The present study reported a novel miRNA (miR-1226-3p) and investigated its function in osteosarcoma. miR-1226-3p mimics and miR-1226-3p antisense oligonucleotides were transfected into human osteosarcoma SaOS-2 cells to alter miR-1226-3 expression, while the hFOB 1.19 cell line was used as the control. The apoptosis rate was analyzed using a dead cell apoptosis kit. TNF receptor-associated factor 3 (TRAF3) protein expression was assayed by western blotting. The results of bioinformatics and clinical specimen analyses revealed that higher expression levels of miR-1226-3p were associated with lower survival rates. Additionally, the results of experiments on cultured cells revealed that miR-1226-3p promoted the proliferation of SaOS-2 cells, while miR-1226-3p inhibition decreased cell proliferation and increased apoptosis. Furthermore, it was revealed that miR-1226-3p targeted TRAF3 in SaOS-2 cells. In conclusion, the present study suggested that miR-1226-3p promoted the proliferation of osteosarcoma cells.  相似文献   

6.
7.
8.
9.
徐律  张炜  胡志  陈旭  褚浩  付桥 《现代肿瘤医学》2022,(23):4233-4238
目的:探讨CTD-2196E14.5通过调控miR-744-5p表达对膀胱癌细胞增殖和侵袭的影响。方法:通过检索TCGA数据库分析膀胱癌组织及癌旁组织中CTD-2196E14.5的表达水平及其与膀胱癌患者总生存期的关系。采用荧光实时定量聚合酶链反应(fluorescence quantitative polymerase chain reaction, qPCR)检测膀胱癌细胞株MGH-U3、T24、253J、J82和正常膀胱上皮细胞SV-HUC-1中CTD-2196E14.5的表达水平。采用脂质体介导技术将pcDNA-CTD-2196E14.5质粒、pcDNA空载质粒分别转染253J细胞,即CTD-2196E14.5组和NC组。采用MTT法、流式细胞术和Transwell实验检测CTD-2196E14.5对膀胱癌253J细胞增殖、细胞周期和侵袭的影响。应用lncRNA2function软件预测和双荧光素酶报告基因实验验证CTD-2196E14.5与miR-744-5p的靶向关系。qPCR检测miR-744-5p的表达。Western blotting检测AMPK信号通路蛋白和细胞周期...  相似文献   

10.
目的:探讨miR-124-3p在鼻咽癌中的表达及其对鼻咽癌细胞的影响及其机制.方法:收集鼻咽癌组织标本90例和慢性鼻咽炎症组织标本85例,运用qRT-PCR方法检测组织标本和CNE1、CNE2、SUNE1、HONE1、5-8F、6-10B及C666-1鼻咽癌细胞株和永生化鼻咽上皮细胞NP69中miR-124-3p的表达,脂质体介导的转染方法下调高表达miRNA-124-3p的鼻咽癌细胞株CNE2,同时上调低表达miRNA-124-3p的鼻咽癌细胞株C666-1.CCK8法、流式细胞技术、细胞划痕实验、Transwell实验和Boyden小室检测细胞增殖、凋亡、迁移及侵袭的变化;生物信息学靶基因预测miRNA-124-3的靶基因并运用荧光素酶报告实验验证,Western Blotting检测细胞中STAT3及其下游的p-STAT3、CCND2和MMP2蛋白表达水平.结果:鼻咽癌组织中miRNA-124-3p表达水平与慢性鼻咽炎症组织相比明显下调(P <0.001);miRNA-124-3p的表达水平与肿瘤大小及范围、区域淋巴结受累情况及临床分期显著相关(均P<0.001);7种鼻咽癌细胞与NP69细胞相比较,miRNA-124-3p的表达水平均显著低于NP69(均P<0.05).miRNA-124-3p过表达后C666-1细胞增殖、凋亡、迁移和侵袭均显著低于空白对照组和mimics NC组(均P<0.05);miRNA-124-3p抑制后CNE2细胞的增殖、凋亡、迁移和侵袭均显著高于inhibitor NC组和空白对照组(均P<0.05).转染miRNA-124-3p后C666-1细胞STAT3、p-STAT3、CCND2和MMP2的表达显著降低,抑制CNE2细胞的miRNA-124-3p表达后STAT3、p-STAT3、CCND2和MMP2的表达显著降低.结论:miR-124-3p可通过下调靶基因STAT3的表达,进而影响其下游的p-STAT3、CCND2和MMP2信号通路,从而促进鼻咽癌细胞凋亡,抑制鼻咽癌细胞的增殖、迁移及侵袭.  相似文献   

11.
The metastasis of osteosarcoma is a major threat to both adolescents and young adults. Identifying novel targets that may prevent osteosarcoma metastasis is critical in developing advanced clinical therapies for treating this cancer. The present study aimed to explore the mechanism of microRNA (miR)-545-5p in the metastasis of osteosarcoma. The present study identified miR-545-5p as a potential target that was downregulated in both osteosarcoma clinical samples and cell lines, and in the latter, ectopically expressed miR-545-5p caused apoptosis. In addition, miR-545-5p exerted inhibitory effects in osteosarcoma migration and invasion. Overexpression of miR-545-5p induced xenograft growth inhibition in vivo. In addition, miR-545-5p targeted dimethyladenosine transferase 1 (DIMT1), an oncogenic protein that facilitates osteosarcoma proliferation, migration and invasion. Taken together, the results of the present study suggest that miR-545-5p functions as a tumor suppressor in osteosarcoma that promotes apoptosis, while inhibiting migration and invasion by targeting DIMT1. Taken together, the results of the present study suggest two potential novel targets for osteosarcoma treatment and metastasis prevention.  相似文献   

12.
[摘要] 目的:检测微小RNA-380-5p(miR-380-5p)在人宫颈癌组织和细胞系中的表达,探讨其抑制宫颈癌C33A细胞增殖和迁移的作用机制。方法:收集2016 年12 月至2017 年7 月同济医学院附属武汉中心医院妇产科手术切除的16 例宫颈癌患者癌组织和对应的癌旁组织标本,以及宫颈癌细胞系HCC94、C33A、Hela、SiHa 和人子宫颈上皮永生化细胞H8,用qPCR 法检测miR-380-5p 在癌及癌旁组织、4 种宫颈癌细胞及H8 细胞中的表达。用脂质体转染技术将miR-380-5p mimic(实验组)和miR-NC(阴性对照组)瞬时转染C33A细胞,用qPCR法检测转染后细胞中miR-380-5p 表达,CCK-8 法和Transwell 小室法分别检测转染细胞的增殖和迁移能力。用生物信息学软件TargetScan 预测miR-380-5p 的下游基因,用双荧光素酶报告基因实验验证miR-380-5p 对下游基因Ras 同源基因家族成员A(Ras homolog gene family member A,RHOA)的结合作用,qPCR 法和Western blotting 检测miR-380-5p 下游基因RHOA的表达。结果:宫颈癌组织中miR-380-5p 表达水平明显低于癌旁组织(P<0.01),宫颈癌细胞系中miR-380-5p 表达水平均明显低于H8 细胞(P<0.05),以C33A细胞中的表达水平最低(P<0.01)。与阴性对照组比较,转染miR-380-5pmimic 能显著抑制C33A细胞的增殖(P<0.05)和迁移能力(P<0.01),且下调RHOA、ROCK1、ROCK2、CDK2和N-cadherin蛋白的表达(均P<0.01)。生物信息学软件预测RHOA可能为miR-380-5p 的调控基因,双荧光素酶报告基因实验结果显示miR-380-5p 可与RHOA 3’-非编码区(UTR)特异性结合,miR-380-5p 可明显下调RHOA基因的表达(P<0.01)。结论:miR-380-5p 在宫颈癌组织及细胞系中低表达,过表达miR-380-5p 可能通过下调RHOA及其下游蛋白的表达抑制宫颈癌C33A细胞的增殖和迁移。  相似文献   

13.
14.
目的: 以反义寡核苷酸技术研究microRNA-17-5p(miR-17-5p)对人慢性髓系白血病K562细胞增殖的影响及其可能的机制。 方法: 脂质体法将miR-17-5p反义寡核苷酸(miR-17-5p antisense oligonucleotide,miR-17-5p-ASO)和对照无义寡核苷酸(control nonsense oligonucleotide,Ctrl-NSO)转染入K562细胞,同时设未转染对照组(Ctrl)。 MTT法检测K562细胞的增殖,TUNEL法检测K562细胞的凋亡,流式细胞术检测K562细胞周期的改变。 结果: MTT检测结果显示,miR-17-5p-ASO组K562细胞增殖活性为Ctrl-NSO组的(61.7±4.7)%,miR-17-5p-ASO转染显著抑制K562细胞的增殖(P<0.05)。TUNEL检测显示,miR-17-5p-ASO转染不影响K562细胞凋亡(P>0.05);miR-17-5p-ASO组K562细胞G2期细胞比例为(10.8±08)%,显著低于Ctrl-NSO组和Ctrl组的(34.6±0.4)%和(33.9±1.3)%(P<0.05)。 结论: MiR-17-5p反义寡核苷酸可以通过调控细胞周期抑制K562细胞的增殖,有望成为白血病治疗的新手段。  相似文献   

15.
16.
Background: MicroRNA-145-5p (miR-145-5p) reportedly inhibits hepatocellular carcinoma (HCC) by targetingARF6, SPATS2, CDCA3, KLF5, and NRAS, indicating that miR-145-5p plays an important role in the occurrenceand development of HCC by regulating the expression of various genes. In this study, we aimed to explore noveldownstream targets of miR-145-5p and elucidate the potential mechanism of miR-145-5p in HCC. Materials andMethods: A bioinformatics analysis was performed to determine the clinical significance of miR-145-5p andalpha/beta hydrolase domain-containing protein 17C (ABHD17C) in patients with HCC. The ability of Hep3Bcells to proliferate, migrate, and invade was examined after overexpression of miR-145-5p and ABHD17C orknockdown of ABHD17C. Tumorigenesis of Hep3B cells overexpressing miR-145 was detected using in vivoexperiments. Results: miR-145-5p was downregulated in HCC tissues, and this was associated with poor prognosis in patients with HCC. Based on the bioinformatics analysis, miR-145-5p was predicted to target ABHD17C,as demonstrated by a luciferase reporter assay. ABHD17C downregulation inhibited cell viability, migration, andinvasion and arrested the cell cycle. Overexpression of miR-145-5p significantly reduced the expression ofABHD17C. Moreover, ABHD17C expression was elevated in HCC tissues, which was associated with an unfavorable prognosis. Re-expressing ABHD17C into HCC cells rescued the suppressed cell viability, migration, andinvasion mediated by ectopic expression of miR-145-5p. Importantly, miR-145-5p suppressed tumor growth inmice and downregulated the levels of Ki67 and ABHD17C in tumor. Conclusion: miR-145-5p could attenuateHCC progression via suppressing ABHD17C.  相似文献   

17.
18.
目的:探讨miR-195-5p 通过靶向FGF2 抑制子宫内膜癌HEC-1B细胞增殖、凋亡、侵袭和迁移的分子机制。方法:HEC-1B细胞培养与转染完成后分为4 组:HEC-1B组、miR-195-5p mimic组、pLV-FGF2 组和miR-195-5p+FGF2 组。qRT-PCR检测细胞miR-195-5p 和FGF2 mRNA水平,荧光素酶实验验证miR-195-5p 与FGF2 的靶向关系,Western blotting 检测FGF2 表达水平,CCK-8 法检测HEC-1B细胞增殖水平,流式细胞术检测HEC-1B细胞凋亡率,Transwell 实验检测HEC-1B细胞侵袭能力,划痕实验检测HEC-1B细胞迁移能力。结果:与HEC-1B组相比,miR-195-5p mimic 组miR-195-5p 表达升高、FGF2 mRNA水平下降(均P< 0.01);miR-195-5p 可直接靶向FGF2。与HEC-1B组相比,miR-195-5p mimic 组FGF2 的蛋白表达水平下降,pLV- FGF2 组FGF2 的蛋白水平明显上升,且miR-195-5p+FGF2 组FGF2 的蛋白表达水平低于pLV- FGF2 组(均P< 0.01)。miR-195-5p mimic 组细胞增殖水平低于HEC-1B组,pLV-FGF2 组细胞增殖水平高于HEC-1B组(均P< 0.01)。与HEC-1B组相比,miR-195-5p mimic 组细胞凋亡率增加,pLV- FGF2 组细胞凋亡率降低,且miR-195-5p+ FGF2 组细胞凋亡率高于pLV- FGF2 组(均P< 0.01)。与HEC-1B组相比,miR-195-5p mimic 组每个视野下的侵袭细胞数和划痕愈合率下降,pLV- FGF2 组每个视野下的侵袭细胞数和划痕愈合率上升,且miR-195-5p+FGF2 组每个视野下的侵袭细胞数和划痕愈合率低于pLV- FGF2 组(均P<0.01)。结论: miR-195-5p 通过靶向FGF2 抑制子宫内膜癌HEC-1B细胞的增殖、侵袭和迁移并促进细胞凋亡,其作为子宫内膜癌的治疗靶点。  相似文献   

19.
20.
目的:探讨miR-875-5p对胃癌细胞增殖、迁移和侵袭的影响及其机制。方法:采用qPCR法检测胃癌细胞BGC-823、HGC-27、MGC-803、SGC-7901、AGS、MKN-45和胃黏膜上皮细胞GES-1中miR-875-5p的表达水平。利用脂质体转染技术,分别将miR-875-5p模拟物/抑制剂(mimic/inhibitor)及其阴性对照质粒(miR-NC/Anti-miR-NC)转染至AGS细胞/MKN-45细胞,构建过表达/抑制miR-875-5p的细胞模型,空白对照组(Control组)不转染。通过CCK-8、克隆形成、Transwell等实验分别检测miR-875-5p表达变化对细胞增殖、克隆形成、迁移和侵袭的影响。采用双荧光素酶报告基因实验验证miR-875-5p与上游刺激因子2(USF2)的靶向关系,WB实验验证miR-875-5p对USF2的调控作用并检测USF2蛋白的表达。构建MKN-45细胞裸鼠移植瘤模型,验证miR-875-5p过表达对MKN-45细胞成瘤能力的影响。结果:miR-875-5p在6种胃癌细胞中表达水平显著低于胃黏膜上皮细胞GES-1(均P<0.01)。与Control组和miR-NC组相比,miR-875-5p mimic组AGS细胞的增殖、克隆形成率、迁移和侵袭细胞数,以及USF2蛋白的表达均显著降低(P<0.05或P<0.01);miR-875-5p inhibitor组MKN-45细胞的增殖、克隆形成率、迁移和侵袭细胞数,以及USF2蛋白的表达均显著提高(P<0.05或P<0.01)。双荧光素酶报告基因实验证明,miR-875-5p能够直接靶向USF2基因。体内成瘤实验结果表明,过表达miR-875-5p显著抑制MKN-45细胞移植瘤的生长(均P<0.01)。结论:miR-875-5p通过靶向USF2抑制胃癌细胞的增殖、迁移和侵袭。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号